Semax vs Selank: Cognitive Peptides Research Comparison

Research Use Only. This article discusses compounds and methods studied in preclinical research and laboratory contexts. Products supplied by Omnix Peptides are intended for in vitro research and laboratory use only — not for human consumption, animal consumption outside approved preclinical research, therapeutic application, or clinical use.

The cognitive-research peptide class includes synthetic compounds derived from naturally-occurring sequences with reported effects on cognition, attention, neurotrophic signaling, and stress response in preclinical research models. Two of the most extensively studied are semax and selank — heptapeptides that share a structural design pattern (a short bioactive fragment stabilized with a C-terminal Pro-Gly-Pro extension) but derive from different parent sequences and act through distinct mechanisms.
This guide compares the two compounds on origin, structure, proposed mechanism, and research applications, with discussion of how their distinct profiles inform compound selection for cognitive research models.

Semax: ACTH-derived heptapeptide in research

Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH). The peptide sequence corresponds to ACTH(4-7) with an additional Pro-Gly-Pro extension at the C-terminus, producing a compound with cognitive and neurotrophic activity in preclinical research models but without the steroidogenic effects of full-length ACTH.
The Pro-Gly-Pro tripeptide extension confers metabolic stability — the modified C-terminus resists carboxypeptidase degradation, extending plasma half-life compared to the parent ACTH(4-7) fragment.
Structural summary:

• Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
• Length: 7 amino acids
• Source: Synthetic, derived from ACTH(4-7) with Pro-Gly-Pro extension

• Common research strengths: 5-50 mg per vial (lyophilized); 30-50 mg per spray (liquid research form)
  Proposed research mechanisms:
  Research on semax has identified:

• Upregulation of brain-derived neurotrophic factor (BDNF) expression in research models

• Modulation of melanocortin pathways
• Effects on dopaminergic and serotonergic neurotransmission in research models
• Neuroprotective effects in research models of ischemic injury
• Effects on attention and short-term memory in behavioral research models
  The most prominent mechanism in research literature is BDNF upregulation, which provides a plausible link between the molecular action and cognitive/neurotrophic outcomes observed in preclinical research models.

Selank: tuftsin-derived heptapeptide in research

Selank is a synthetic heptapeptide derived from a fragment of tuftsin, an immunomodulatory peptide found in the Fc portion of immunoglobulin G. Selank’s sequence is the tuftsin tetrapeptide (Thr-Lys-Pro-Arg) with the same Pro-Gly-Pro C-terminal extension used in semax to confer metabolic stability.
The structural parallel to semax is intentional — both compounds use the Pro-Gly-Pro stabilizing motif on a short bioactive sequence, producing peptides with extended half-life relative to the parent fragments.
Structural summary:

• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
• Length: 7 amino acids
• Source: Synthetic, derived from tuftsin with Pro-Gly-Pro extension

• Common research strengths: 5-10 mg per vial (lyophilized); 40 mg per spray (liquid research form)
  Proposed research mechanisms:
  Research on selank has identified:

• Modulation of GABAergic signaling in research models

• Effects on serotonin metabolism
• Anxiolytic-pattern effects in stress and anxiety research models
• Cognitive effects in attention and learning research paradigms
• Immune modulation deriving from tuftsin-pathway relationships
  Selank’s profile distinguishes from semax in research by its stronger anxiolytic-pattern effects in preclinical stress models, alongside cognitive effects. The two compounds are often studied in parallel in research designs comparing stress-related cognitive performance.

A note on dihexa

This comparison originally planned to include dihexa, an angiotensin-IV-derived peptide studied for synaptic plasticity research. Dihexa is excluded from this comparison because the two foundational mechanism papers describing dihexa’s reported action through the hepatocyte growth factor (HGF) / c-Met receptor pathway — Kawas et al. (2012) and Benoist et al. (2014), both published in the Journal of Pharmacology and Experimental Therapeutics — were retracted in April 2025 following a Washington State University investigation that identified falsified and fabricated data. The retraction does not establish that dihexa has no biological activity, but it does mean the primary mechanism literature should not be cited as if it were established research. Researchers interested in dihexa for preclinical work should review the current state of the independent replication literature directly before designing experiments.

Side-by-side research comparison

Selection considerations for research applications

When semax is the research focus

Semax is the appropriate research selection when:

• The research question concerns BDNF upregulation specifically
• Research models of ischemic injury and neuroprotection are the focus
• Attention, working memory, or short-term cognitive performance is the primary research outcome
• Comparison with ACTH-pathway-derived compounds is part of the research design

When selank is the research focus

Selank is the appropriate research selection when:

• The research question concerns anxiety-related cognitive performance
• GABAergic modulation is a target research mechanism
• Stress-related research models of cognitive function are the focus
• Parallel comparison with semax in cognitive-anxiety research designs is the experimental approach

Research-design considerations

Cross-compound cognitive research

A common research design compares semax and selank in parallel within a single experimental framework, taking advantage of their shared structural design and contrasting mechanism profiles. Typical structure:

• Vehicle control
• Semax at matched research dose ranges
• Selank at matched research dose ranges
• Behavioral and biochemical outcomes assessed in parallel
  Dose-matching across these compounds is non-trivial in research because the mechanisms differ — comparable molar quantities do not produce comparable receptor or pathway engagement. Pilot research studies typically establish compound-specific dose-response curves before head-to-head comparisons.

Form factor and research administration

Both compounds are available in common research forms:

• Semax: lyophilized vial or liquid spray (intranasal-pattern research models)
• Selank: lyophilized vial or liquid spray
  Selection of form factor depends on the research model. Lyophilized vials provide maximum flexibility for dose-response research. Liquid sprays support specific administration-route research, particularly for intranasal-pattern preclinical work where the parent literature also used intranasal administration.

Storage and stability

Standard research peptide storage applies to both:

• Lyophilized vials at 2-8°C (short-term) or -20°C (long-term)
• Reconstituted solutions at 2-8°C for 2-4 weeks
• Liquid sprays at refrigerated storage with stability per supplier documentation

Frequently asked questions

Q: Are semax and selank equivalent compounds in research?
A: No. They act through different mechanisms and have distinct research-application profiles. Semax primarily affects BDNF in research models; selank primarily affects GABAergic and serotonergic signaling.
Q: Why do semax and selank have similar structures?
A: Both are short bioactive peptide fragments extended with the same C-terminal Pro-Gly-Pro tripeptide. The Pro-Gly-Pro extension confers metabolic stability against carboxypeptidase degradation. The bioactive portions (ACTH(4-7) and tuftsin) are different and account for the distinct mechanism profiles in research.
Q: Can these compounds be used together in research designs?
A: Combination research designs exist but are less common than single-compound studies. The distinct mechanisms allow combination research where research questions concern multi-pathway effects on cognition and stress response.
Q: Which compound has more research literature behind it?
A: Both have substantial preclinical research literature, much of it originating from Russian neuroscience groups. Semax has slightly broader cross-translation into English-language research literature; selank’s literature is more concentrated in anxiety and stress research contexts.
Q: What is the typical purity of research-grade semax and selank?
A: Research-grade synthetic preparations typically certify at ≥98% purity by RP-HPLC, with mass-spectrometric identity confirmation. Premium-grade preparations certify ≥99%.

Further reading

• Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. “Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.” Cell Mol Neurobiol 2010;30(1):71-79. PMID: 19633950 | DOI: 10.1007/s10571-009-9432-0
• Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, Miasoedov NF. “[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].” Zh Nevrol Psikhiatr Im S S Korsakova 2014;114(7):17-22. Russian. PMID: 25176261

Important Notice — Research Use Only
All compounds discussed in this article are described exclusively in the context of laboratory research and preclinical study. Products supplied by Omnix Peptides are intended for in vitro research and laboratory use only. They are not for human consumption, are not for animal consumption outside of approved preclinical animal research, are not intended to diagnose, treat, cure, or prevent any disease, and have not been approved by the FDA for any therapeutic application.
This article makes no claims regarding efficacy, safety, or appropriateness of these compounds for any application outside controlled research settings. Researchers using these compounds are responsible for compliance with all applicable laws, regulations, and institutional review requirements. Information in this article does not constitute medical, veterinary, or scientific advice for any application outside controlled research settings.